Replimune's Second Quarter Fiscal 2027 Earnings Conference Call - REPLIMUNE GROUP INC

Explicit Guidance:

• Financial Guidance: Management explicitly stated they will not provide revenue guidance at this time due to the early stage of the commercial launch.
• Cash Runway: Based on the current operating plan (including commercial launch investments and funding for the IGNITE3/REVEAL study), the company expects its cash position to fund operations for greater than 12 months.
• Listing Timeline: The company anticipates the miscellaneous J code to be replaced by a permanent J code by April 20, 2027.

Business-Segment Outlook:

• Commercial Launch Trajectory: The company aims to double the number of accounts initiating patients by the end of the fiscal year (relative to the ~20 accounts currently treating patients).
• Account Penetration: The immediate priority (first six months) focuses on the top 200 accounts, which represent ~30% of annual US melanoma cases. Management expects to accelerate into the next wave of 250 accounts (representing an additional 20% of the population) as readiness allows.
• Prescribing Volume: A course of therapy is listed at $450,000 (pre-rebates); patients may receive eight or more cycles over several months, with revenue potentially recognized over multiple quarters.
• Pipeline Enrollment: The REVEAL study in uveal melanoma and the confirmatory melanoma study (I3) in Europe are currently enrolling very well.

Market and Competitive Outlook:

• Demand & Adoption: Management cites "real urgency" and "unmet need" among physicians treating PD-1-refractory melanoma. Early data shows over 70% engagement with the initial 200 target accounts, with ~20 accounts on formulary and 15+ institutions having written prescriptions.
• Formulary & Access: There is a trend of institutions expediting or bypassing standard formulary reviews to treat patients quickly. Most commercial payers have published coverage policies supporting the label (including retreatment), covering a majority of commercially covered lives.
• Payer Policy Impact: Policies do not restrict volume (allowing doses up to 24 cycles/retreatment) or restrict usage to specific lesion types, facilitating broader adoption.

Macro / Industry Outlook:

• Treatment Landscape: Management observes that physicians are positioning TudraCav for use both early and later lines of therapy following PD-1 progression, including in the adjuvant setting, rather than strictly as a last-resort option.
• Operational Dynamics: There is strong interest from interventional radiologists to integrate image-guided injections into standard workflows, with no significant operational hold-ups reported so far.

Strategic Initiatives:

• Commercial Team Rebuild: The sales force and customer-facing team are now almost fully staffed and right-sized, with 23 account management positions filled, focusing on executing the launch plan and expanding beyond the initial 200 accounts.
• Supply Chain Readiness: The company has over a year of inventory on hand at its in-house manufacturing facility and supports next-day delivery to patients.
• Patient Support: The "RepliMune and Connect Plus" patient support program is live to facilitate access and compliance.

Risks and Headwinds to Outlook:

• Metric Disclosure Constraints: The company cannot yet provide patient volume metrics due to variable dosing based on tumor burden; they will provide insights on average volume only once a cohort completes eight or more cycles.
• Operational Variability: While no major bottlenecks exist, individual account onboarding speeds vary due to differing internal processes (e.g., Pharmacy & Therapeutics committee schedules).
• Forward-Looking Disclaimers: Actual results may differ materially due to risks detailed in the company's Form 10-K and Form 10-Q, including uncertainties surrounding the commercial launch.

Management Tone on the Future:

• Confidence Level: Management expresses high confidence and "encouragement" regarding the launch, citing "great interest" from physicians and "excellent" early traction.
• Strategic Pacing: Despite the positive early demand, leadership emphasizes a "do it right" philosophy, prioritizing patient and physician experience and repeat treatments over rapid, potentially suboptimal expansion.
• Momentum: The tone suggests accelerating adoption, with expectations to see even more accounts "come online" in the coming weeks and months.

Miscellaneous:

• Segment Definition: First commercial shipments occurred in early October 2026, meaning the first product revenue will be reported in Fiscal Q3.
• Q3 Financials (Context): Q2 2027 showed an R&D expense of $34.4M and SG&A of $21.9M, with a net loss of $57.1M, ending the quarter with $307.8M in cash.